BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

540 related articles for article (PubMed ID: 16632184)

  • 1. Should bladder biopsies be performed routinely after bacillus Calmette-Guérin treatment for high-risk superficial transitional cell cancer of the bladder?
    Guy L; Savareux L; Molinié V; Botto H; Boiteux JP; Lebret T
    Eur Urol; 2006 Sep; 50(3):516-20; discussion 520. PubMed ID: 16632184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discrepancies between cytology, cystoscopy and biopsy in bladder cancer detection after Bacille Calmette-Guerin intravesical therapy.
    Hara T; Takahashi M; Gondo T; Nagao K; Ohmi C; Sakano S; Naito K; Matsuyama H
    Int J Urol; 2009 Feb; 16(2):192-5. PubMed ID: 19054166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients.
    Peyromaure M; Guerin F; Amsellem-Ouazana D; Saighi D; Debre B; Zerbib M
    J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer.
    Fernandez-Gomez J; Rodríguez-Martínez JJ; Barmadah SE; García Rodríguez J; Allende DM; Jalon A; Gonzalez R; Alvarez-Múgica M
    Eur Urol; 2007 May; 51(5):1267-74. PubMed ID: 17207912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
    Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
    Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
    Thalmann GN; Sermier A; Rentsch C; Möhrle K; Cecchini MG; Studer UE
    J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
    Kumar A; Kumar R; Gupta NP
    Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bacillus Calmette-Guerin in the treatment of stage T1 grade 3 transitional cell carcinoma of the bladder: long-term results.
    Pansadoro V; Emiliozzi P; Defidio L; Donadio D; Florio A; Maurelli S; Lauretti S; Sternberg CN
    J Urol; 1995 Dec; 154(6):2054-8. PubMed ID: 7500457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin.
    Brake M; Loertzer H; Horsch R; Keller H
    J Urol; 2000 Jun; 163(6):1697-701. PubMed ID: 10799163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of intravesical instillation on performance of uCYT+ test.
    Lodde M; Mian C; Negri G; Vittadello F; Comploj E; Palermo S; Staffler A; Brössner C; Pycha A
    Urology; 2004 May; 63(5):878-81. PubMed ID: 15134970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?
    Wo JY; Shipley WU; Dahl DM; Coen JJ; Heney NM; Kaufman DS; Zietman AL
    BJU Int; 2009 Jul; 104(2):179-83. PubMed ID: 19154448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cytoscopic follow-up of initial G3T1 bladder tumors treated with BCG].
    Pieras Ayala E; Palou J; Rodríguez-Villamil L; Millán Rodríguez F; Salvador Bayarri J; Vicente Rodríguez J
    Arch Esp Urol; 2001 Apr; 54(3):211-7. PubMed ID: 11432035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer.
    Cheng CW; Chan SF; Chan LW; Chan CK; Ng CF; Cheung HY; Chan SY; Wong WS; Lai FM; To KF; Li ML
    Int J Urol; 2005 May; 12(5):449-55. PubMed ID: 15948743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing treatment response after induction Bacillus Calmette-Guerin for carcinoma in situ of the urinary bladder: can post-induction random bladder biopsies be avoided?
    Smith PJ; Lotan Y; Raj GV; Sagalowsky AI; Margulis V
    Cytopathology; 2014 Apr; 25(2):108-11. PubMed ID: 23551700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
    Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED
    J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hexylaminolaevulinate fluorescence cystoscopy in patients previously treated with intravesical bacille Calmette-Guérin.
    Ray ER; Chatterton K; Khan MS; Chandra A; Thomas K; Dasgupta P; O'Brien TS
    BJU Int; 2010 Mar; 105(6):789-94. PubMed ID: 19832725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An analysis of the effect of statin use on the efficacy of bacillus calmette-guerin treatment for transitional cell carcinoma of the bladder.
    Berglund RK; Savage CJ; Vora KC; Kurta JM; Cronin AM
    J Urol; 2008 Oct; 180(4):1297-300; discussion 1300. PubMed ID: 18707737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bacillus Calmette-Guérin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression.
    Andius P; Holmäng S
    BJU Int; 2004 May; 93(7):980-4. PubMed ID: 15142147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumors.
    Palou J; Laguna P; Millán-Rodríguez F; Hall RR; Salvador-Bayarri J; Vicente-Rodríguez J
    J Urol; 2001 May; 165(5):1488-91. PubMed ID: 11342902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical utility of fluorescent in situ hybridization for the surveillance of bladder cancer patients treated with bacillus Calmette-Guérin therapy.
    Mengual L; Marín-Aguilera M; Ribal MJ; Burset M; Villavicencio H; Oliver A; Alcaraz A
    Eur Urol; 2007 Sep; 52(3):752-9. PubMed ID: 17379395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.